SCHEMBL3013350

SCHEMBL3013350

Cc1ccccc1Cc1csc(N2CCN(S(=O)(=O)c3cc(F)ccc3C)CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MEN1 O00255 3/20 0.46
LMNA P02545 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.43
RAB9A P51151 2/20 0.42
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
KDM4E B2RXH2 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
USP2 O75604 1/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MAPK1 P28482 3/20 0.41
POLB P06746 2/20 0.41
TSHR P16473 2/20 0.40
HTT P42858 1/20 0.40
DCTPP1 Q9H773 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011989 0.93 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3002474 0.92 GBA1 (0.46) ALDH1A1SMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3019053 0.91 MAPT (0.45) ALDH1A1SMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3017589 0.91 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3007521 0.91 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3021385 0.90 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3003394 0.90 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3017462 0.87 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3009247 0.87 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3016995 0.87 KMT2A (0.47) ALDH1A1SMN1; SMN2MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.